ANI Pharmaceuticals (ANIP)

[Just the facts maam]

I agree Homeslice, and BPAX management has not helped,nor has this management, in getting the street to treat ANI on par with similar companies.

Przybyl stated in our conversation that he wanted to get one year under his belt before pro-actively doing presentations. ANI didn't need to raise money like a small biotech to keep afloat. He said he would like a full year of financial data clear of Biosante and the merger. On the other hand he also said he would work to get us to small cap territory ($30 PPS), where he feels it will get more fairly traded, ASAP. Hopefully the reports about meeting with Oppenheimer are accurate and it helps get us there.

In any event the quarterly EPS X 164 (average of multiple of similar companies regardless of size) appears to be fair once the company establishes credibility with the street.

Many on this Board still think of it as BPAX, even though it is a new company with new management. If the street thinks the same Przybyl, has to work to shake that belief. Four quarters of increasing profits will definitely help his case. Lets hope that starts November 7th.